Ainara Soria-Rivas

Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors

Iván Márquez‐Rodas, Federico Longo, María E. Rodríguez-Ruiz et al. · Science Translational Medicine · 2020 · 84 citations

Life Sciences, Immunology, Oncology +16

A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6

Brett Hughes, Alexander Guminski, Samantha Bowyer et al. · Journal of the American Academy of Dermatology · 2024 · 59 citations

Medicine, Dermatology, Oncology +15

Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma

L. Alonso-Castro, L. Ríos‐Buceta, Sérgio Vañó-Galván et al. · Journal of the American Academy of Dermatology · 2013 · 20 citations

Medicine, Oncology, Pharmacotherapy +12

Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital

Javier Torres-Jiménez, Jorge Esteban-Villarrubia, P. García‐Abellás et al. · Clinical & Translational Oncology · 2021 · 13 citations

Medicine, Immunology, Oncology +14

Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology

José Trigo, Mónica García‐Cosío, Almudena García‐Castaño et al. · Clinical & Translational Oncology · 2022 · 10 citations · Full text

Medicine, Oncology, Pathology +14